Company profile
BioRestorative Therapies, Inc.
NASDAQ:BRTXManaged Health Care
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04042844 | phase2 | recruiting | 2022-06-30 | 2026-12-01 | BioRestorative Therapies | A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD) |
FDA applications (0)
No records yet.